BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.

(NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more ...

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...

DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus Estimate of 65 cents by 4.6%. The company reported adjusted earnings of 45 ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over last year's supply shortage of the company's leading diabetes product. Leach ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, ...